Skip to main content

Table 3 Comparison of HAE attacks treated with icatibant and untreated attacks

From: Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom

Parameter

Patients with HAE type I or II

UK

N = 73

Non-UK

N = 579

Icatibant-treated attacksa

 Patients treated with icatibant, n

58

436

 Attacks treated with icatibant per patient

  Mean (SD)

7.5 (12.8)

7.6 (12.5)

  Median (IQR)

3.0 (1.0, 6.0)

3.0 (1.0, 8.0)

Untreated attacks in year prior to IOS entryb

 Patients with at least one untreated attack, n

46c

219d

 Untreated attacks per patient

  Mean (SD)

8.5 (16.8)

7.4 (14.0)

  Median (IQR)

2.0 (0, 5.0)

2.0 (0, 8.0)

Untreated attacks in the IOS observation perioda

 Patients with at least one untreated attack, n

30e

198f

 Untreated attacks per patient

  Mean (SD)

10.9 (23.2)

8.2 (17.3)

  Median (IQR)

2.0 (0.0, 8.0)

1.0 (0, 8.0)

  1. HAE hereditary angioedema, IOS Icatibant Outcome Survey, IQR interquartile range, SD standard deviation
  2. aAttacks in year prior to IOS entry and through the IOS observation period
  3. bUntreated attacks were defined as attacks not treated with icatibant or any other treatment
  4. c19 patients had no untreated attacks
  5. d114 patients had no untreated attacks
  6. e22 patients had no untreated attacks
  7. f150 patients had no untreated attacks